$MNOV
MEDICINOVA INC

2024 Q4 Form 10-Q Financial Statement

#000095017024126343 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.450M
YoY Change 7.39%
% of Gross Profit
Research & Development $1.800M
YoY Change 157.14%
% of Gross Profit
Depreciation & Amortization $5.180K
YoY Change
% of Gross Profit
Operating Expenses $3.309M
YoY Change 54.14%
Operating Profit -$3.309M
YoY Change 188.53%
Interest Expense $447.9K
YoY Change 1.78%
% of Operating Profit
Other Income/Expense, Net $9.102K
YoY Change -164.31%
Pretax Income -$2.852M
YoY Change 296.14%
Income Tax
% Of Pretax Income
Net Earnings -$2.852M
YoY Change 294.43%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share -$0.06
COMMON SHARES
Basic Shares Outstanding 49.05M 49.05M
Diluted Shares Outstanding 49.05M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.28M
YoY Change -17.9%
Cash & Equivalents $42.28M
Short-Term Investments
Other Short-Term Assets $984.9K
YoY Change 96.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $43.27M
YoY Change -18.36%
LONG-TERM ASSETS
Property, Plant & Equipment $30.81K
YoY Change -39.87%
Goodwill $9.600M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $19.00K
YoY Change -73.27%
Total Long-Term Assets $14.85M
YoY Change -1.89%
TOTAL ASSETS
Total Short-Term Assets $43.27M
Total Long-Term Assets $14.85M
Total Assets $58.12M
YoY Change -14.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $708.2K
YoY Change -3.89%
Accrued Expenses $1.889M
YoY Change -10.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.597M
YoY Change -7.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $255.2K
YoY Change -44.99%
Total Long-Term Liabilities $255.2K
YoY Change -44.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.597M
Total Long-Term Liabilities $255.2K
Total Liabilities $3.054M
YoY Change -11.92%
SHAREHOLDERS EQUITY
Retained Earnings -$423.9M
YoY Change 2.49%
Common Stock $479.1M
YoY Change 0.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $55.07M
YoY Change
Total Liabilities & Shareholders Equity $58.12M
YoY Change -14.7%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.852M
YoY Change 294.43%
Depreciation, Depletion And Amortization $5.180K
YoY Change
Cash From Operating Activities -$2.032M
YoY Change 48.32%
INVESTING ACTIVITIES
Capital Expenditures $10.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $200.00
YoY Change
Cash From Investing Activities $190.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -2.032M
Cash From Investing Activities 190.0
Cash From Financing Activities
Net Change In Cash -2.032M
YoY Change 48.31%
FREE CASH FLOW
Cash From Operating Activities -$2.032M
Capital Expenditures $10.00
Free Cash Flow -$2.032M
YoY Change 48.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001226616
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33185
dei Entity Registrant Name
EntityRegistrantName
MEDICINOVA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0927979
dei Entity Address Address Line1
EntityAddressAddressLine1
4275 Executive Square
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
373-1500
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
MNOV
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49046246
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42280618
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50999442
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
984860
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
174938
CY2024Q3 us-gaap Assets Current
AssetsCurrent
43265478
CY2023Q4 us-gaap Assets Current
AssetsCurrent
51174380
CY2024Q3 us-gaap Goodwill
Goodwill
9600240
CY2023Q4 us-gaap Goodwill
Goodwill
9600240
CY2024Q3 mnov In Process Research And Development
InProcessResearchAndDevelopment
4800000
CY2023Q4 mnov In Process Research And Development
InProcessResearchAndDevelopment
4800000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30813
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
45800
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
403894
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
575406
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18996
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74151
CY2024Q3 us-gaap Assets
Assets
58119421
CY2023Q4 us-gaap Assets
Assets
66269977
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
708203
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1003937
CY2024Q3 mnov Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1686739
CY2023Q4 mnov Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2059238
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
201976
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
215926
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2596918
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3279101
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
201792
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
201792
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
255150
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
410660
CY2024Q3 us-gaap Liabilities
Liabilities
3053860
CY2023Q4 us-gaap Liabilities
Liabilities
3891553
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49046246
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49046246
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49046246
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49046246
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
49046
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
49046
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
479076908
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
478149161
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-123803
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-118090
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-423936590
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-415701693
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
55065561
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
62378424
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58119421
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66269977
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000000
CY2024Q3 mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
1859400
CY2023Q3 mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
794706
mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
5287318
mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
4007117
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1449728
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1352182
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4204299
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4403044
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
3309128
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2146888
us-gaap Operating Expenses
OperatingExpenses
9491617
us-gaap Operating Expenses
OperatingExpenses
8410161
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3309128
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1146888
us-gaap Operating Income Loss
OperatingIncomeLoss
-9491617
us-gaap Operating Income Loss
OperatingIncomeLoss
-7410161
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
447847
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
437934
us-gaap Interest Income Other
InterestIncomeOther
1280708
us-gaap Interest Income Other
InterestIncomeOther
1398400
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9102
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14153
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23988
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-500670
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2852179
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-723107
us-gaap Net Income Loss
NetIncomeLoss
-8234897
us-gaap Net Income Loss
NetIncomeLoss
-6512431
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49046246
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49046246
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49046246
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49046246
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49046246
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49046246
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49046246
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49046246
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2852179
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-723107
us-gaap Net Income Loss
NetIncomeLoss
-8234897
us-gaap Net Income Loss
NetIncomeLoss
-6512431
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7724
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2712
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5713
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8467
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2844455
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-725819
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8240610
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6520898
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
62378424
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
215430
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2754518
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8892
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
59830444
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
207455
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2628200
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4545
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
57405154
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
504862
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2852179
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7724
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
55065561
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
70242035
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
403263
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2917504
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1542
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
67726252
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
325710
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2871820
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4213
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
65175929
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
219142
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-723107
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2712
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
64669252
us-gaap Profit Loss
ProfitLoss
-8234897
us-gaap Profit Loss
ProfitLoss
-6512431
us-gaap Share Based Compensation
ShareBasedCompensation
927747
us-gaap Share Based Compensation
ShareBasedCompensation
948115
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15900
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14803
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-102513
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
199
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-371
mnov Change In Carrying Amount Of Right Of Use Asset
ChangeInCarryingAmountOfRightOfUseAsset
129179
mnov Change In Carrying Amount Of Right Of Use Asset
ChangeInCarryingAmountOfRightOfUseAsset
146205
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
755820
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
27478
mnov Increase Decrease In Accounts Payable Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities
-665592
mnov Increase Decrease In Accounts Payable Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities
-457675
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-127550
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-146401
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8711232
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6931978
mnov Proceeds From Disposal Of Investments
ProceedsFromDisposalOfInvestments
39929015
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
199
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
897
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21321
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-698
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39907694
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6894
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26152
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8718824
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
33001868
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50999442
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18505493
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42280618
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51507361
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
42281
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
139001
mnov Change In Carrying Amount Of Right Of Use Asset Due To Termination Of Lease
ChangeInCarryingAmountOfRightOfUseAssetDueToTerminationOfLease
79229
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1800000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
700000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000000.0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3700000
CY2024Q3 mnov Patents Expense
PatentsExpense
100000
CY2023Q3 mnov Patents Expense
PatentsExpense
100000
mnov Patents Expense
PatentsExpense
300000
mnov Patents Expense
PatentsExpense
300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</span></p>
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
70720
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
64024
us-gaap Operating Lease Payments
OperatingLeasePayments
204177
us-gaap Operating Lease Payments
OperatingLeasePayments
189622
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
74378
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
64011
us-gaap Operating Lease Cost
OperatingLeaseCost
206228
us-gaap Operating Lease Cost
OperatingLeaseCost
190240
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
201976
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
215926
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
255150
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
410660
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
457126
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
626586
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M21D
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.096
CY2023Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.093
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
59923
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
226646
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
206483
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
17269
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
510321
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
53195
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
457126
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7781749
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1100000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
521905
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.51
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8359844
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.18
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7482344
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.61
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
504862
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
219142
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
927747
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
948115
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.6
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8359844
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8359844
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8304749
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8304749
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-126343-index-headers.html Edgar Link pending
0000950170-24-126343-index.html Edgar Link pending
0000950170-24-126343.txt Edgar Link pending
0000950170-24-126343-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mnov-20240930.htm Edgar Link pending
mnov-20240930.xsd Edgar Link pending
mnov-ex31_1.htm Edgar Link pending
mnov-ex31_2.htm Edgar Link pending
mnov-ex32_1.htm Edgar Link pending
mnov-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mnov-20240930_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending